REPL News and Press, Replimune Group Inc. From 03/21/22

WOBURN, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its executive team and Key Opinion Leaders w...

This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...

WOBURN, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replim...

Replimune Group press release (NASDAQ:REPL): Q3 GAAP EPS of -$0.57 beats by $0.01 As of December 31, 2021, cash, cash equivalents and short-term investments were $420.2 million, as compared to $476.3 million as of March 31, 2021. For further details see: Replimune Gr...

WOBURN, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced Otello Stampacchia, Ph.D., of Omega Funds, has resigned from ...

CERPASS clinical trial with RP1 in CSCC on track to complete enrollment mid-year with the primary analysis trigger six months thereafter IGNYTE anti-PD1 failed melanoma, evaluating RP1 in combination with Opdivo ® on track to release interim data in late 2022 Phase 2...

WOBURN, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replim...

WOBURN, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing a range of product candidates derived from its oncolytic immuno-gene therapy platform, today announced the appointment of Christy Oliger to the Company’s Board of...

RP2 data demonstrates deep and durable responses in difficult to treat cancers both as monotherapy and in combination with Opdivo® (nivolumab) Initiated Phase 1 expansion of RP2 in combination with Opdivo focused on patients with liver metastases WOBURN, Mass., Nov. 1...

BTIG analyst Kaveri Pohlman assumed coverage of Replimune Group (NASDAQ:REPL) with a Buy rating and $60 price target (PT), implying a premium of ~93% from last close. The analyst assumed coverage of 10 more Immuno-oncology companies, and believes "much of the most promising work" involves bro...